Journal of Clinical Epidemiology
Volume 53, Issue 2 , Pages 157-161, February 2000

Why use placebos in clinical trials? A narrative review of the methodological literature

  • Andrew J. Vickers

      Affiliations

    • Integrative Medicine Service and Biostatistics Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 11215, USA
    • Corresponding Author InformationCorresponding author. Tel.: 1-212-639-8629; fax: 1-212-794-5851.
  • ,
  • Anton J.M. de Craen

      Affiliations

    • Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, Netherlands

Received 20 May 1998; received in revised form 16 June 1999; accepted 23 June 1999.

Abstract 

Researchers have a number of different options for their choice of control or comparison intervention in randomized trials. We surveyed the methodological literature looking for reasons why a researcher might choose to administer a placebo (i.e., a mimic intervention) to control subjects. Two implicit assumptions were that the issue of placebo is pertinent only to drug trials and that the nonplacebo effect of a treatment is the “real” or “true” effect. Explicit reasons given in the literature for the use of placebos were facilitating blinding and controlling for the placebo effect. The importance of the latter was often inadequately argued. Reasons to avoid placebos in controlled trials, other than ethics and feasibility, are that placebos do not inform real decisions, and may interfere with accurate estimation of effect size and with nonspecific aspects of treatment. Placebo-controlled trials have high internal validity but may be difficult to apply to clinical practice; the situation is reversed for trials without placebo control.

Keywords:  Placebos, Research design, Double blind method, Clinical trials, Randomised controlled trials

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0895-4356(99)00139-0

Journal of Clinical Epidemiology
Volume 53, Issue 2 , Pages 157-161, February 2000